With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29841-69-8,(1S,2S)-(-)-1,2-Diphenylethylenediamine,as a common compound, the synthetic route is as follows.
Example 4: Preparation of RuCI [ (1 S, 2S)-p-dansylNCH (C6H5) CH (C6H5) NH2] (rl6-p-cymene) a) Preparation of (S, S)-5-dimethylamino-naphthalene-1-sulfonic acid (2-amino-1, 2-diphenyl- ethyl)-amide : To a solution of (S, S)-diphenylethylenediamine (250 mg, 1.2 mmol) and triethylamine (0.5 ml) in THF is added dropwise a solution of dansyl chloride (318 mg, 1.2 mmol) in THF (2 mi) at 0C. After stirring 16 h at RT the solvent is removed in vacuum and the residue is resolved in methylenchloride (20 ml). The organic solution is washed with NaHCO3 solution (5 ml), dried over Na2SO4 and after filtration the solvent is removed. Flash chromatographie afford (S, S)-5-dimethylamino-naphthalene-1-sulfonic acid (2-amino-1,2- diphenyl-ethyl)-amide as yellow oil which crystallizes by drying in vacuum. M: 445. 59. in- NMR (400 MHz, CDCl3) : 8.36 (t, J = 7.5 Hz, 2 H), 8.17 (dd, J = 7.2, 1.2 Hz, 1 H), 7.47 (dd, J = 8.8 Hz, 1 H), 7. 34 (dd, J = 8.5 Hz, 1 H), 7.24-7. 16 (m, 4 H), 7.11 (d, J = 7.5 Hz, 1 H), 6.99- 6.74 (m, 6 H), 4.61 (d, J = 8.5 Hz, 1 H), 4.20 (d, J = 8.5 Hz, 1 H), 2.80 (s, 6 H)
29841-69-8, The synthetic route of 29841-69-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2005/92294; (2005); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI